Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2023 Jul;29(3):521-541.
doi: 10.3350/cmh.2023.0202. Epub 2023 Jul 1.

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho  1 , Jin Woo Choi  2 , Hoon Kwon  3 , Kun Yung Kim  4 , Byung Chan Lee  5 , Hee Ho Chu  5 , Dong Hyeon Lee  6 , Han Ah Lee  7 , Gyoung Min Kim  8 , Jung Suk Oh  9 , Dongho Hyun  10 , In Joon Lee  11 , Hyunchul Rhim  10 ; Research Committee of the Korean Liver Cancer Association
Affiliations
Practice Guideline

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho et al. Clin Mol Hepatol. 2023 Jul.

Abstract

Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.

Keywords: Chemoembolization; Guidance; Guideline; Hepatocellular carcinoma; Recommendations.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Jin Woo Choi reports sponsored lecture for Philips Healthcare; consultant/advisory roles for Philips Healthcare, Taewoong; research grants from Nextbiomedical. Gyoung Min Kim reports sponsored lectures for Boston Scientific. In Joon Lee reports sponsored lectures for Guerbet Korea, Boston Scientific Korea, Cook. Hyunchul Rhim reports a sponsored lecture for STARmed; research grants from Johnson & Johnson. All remaining authors have declared no conflicts of interest.

Figures

Figure 1.
Figure 1.
Interventional radiologist survey on the use of cone-beam computed tomography (CBCT) and microcatheter. cTACE, conventional TACE; DEB-TACE, drug-eluting bead TACE.
Figure 2.
Figure 2.
Extent of treatment depending on the microcatheter position in superselective transarterial chemoembolization (TACE). (A) Nonselective TACE at the right hepatic artery. (B) Superselective TACE at A7 and less selective TACE at the right anterior hepatic artery. (C) Superselective TACE at every tumor-feeding artery.
Figure 3.
Figure 3.
Interventional radiologist survey on chemoembolic agents in conventional transarterial chemoembolization.
Figure 4.
Figure 4.
Drug-eluting bead transarterial chemoembolization (DEB-TACE) vs. conventional transarterial chemoembolization (cTACE). (A) DEBTACE: DEBs cannot reach to the intra-tumoral fine arteries in small hepatocellular carcinoma, and blood supply from the portal venule can remain after DEB-TACE. (B) cTACE: Chemoemulsion can be accumulated in the peri-tumoral portal venules as well as intra-tumoral fine arteries.
See this image and copyright information in PMC

References

    1. Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26:81–96. - PubMed
    1. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148:397–401. - PubMed
    1. Ohishi H, Yoshimura H, Uchida H, Sakaguchi H, Yoshioka T, Ohue S, et al. Transcatheter arterial embolization using iodized oil (lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol. 1989;23 Suppl:S33–S36. - PubMed
    1. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–481. - PubMed
    1. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739. - PubMed

Publication types

LinkOut - more resources